الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 95 |  |  |
| | | from | 95 | | |
Abstract
Breast cancer (BC) is considered the most common malignancy in women and exhibits significant heterogeneity. The molecular type of BC is very important to guide different treatments and to alter the prognosis and the survival of patients. Breast cancer is classified into 4 subtypes based on expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2).
Triple-negative breast cancer (TNBC) defined as “The absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal receptor-2 (HER2)”. It accounts for 15-20% of breast cancer patients, and it shows an aggressive behavior regarding recurrence incidence, response to treatment and survival rate. Regarding Triple-positive breast cancer (TPBC), it is thought that roughly 20-25% of breast cancers are HER2-positive. It was known that TPBC has better response rates, but recently many research observations have proven otherwise. In this retrospective study, we aimed to compare clinic-pathological difference between two groups and assess possible associations of the parameters with recurrence and survival.
Breast cancer patients, attending Clinical Oncology and Nuclear medicine department in Suez Canal University hospital (SCUH), in period between January 2010 till December 2018 and fulfilling the Inclusion Criteria and exclusion criteria were enrolled. They were stratified into two groups according to pattern of hormonal receptor then selection of patients from each group as following:
• group A: Triple-negative breast cancer (TNBC(.
• group B: Luminal B HER2 neu-positive breast cancer / triple positive breast cancer (TPBC).